(5-methyl-2-phenethyl-oxazol-4-yl)-acetic acid methyl ester | 401791-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (5-methyl-2-phenethyl-oxazol-4-yl)-acetic acid methyl ester
• 英文别名: methyl 2-[5-methyl-2-(2-phenylethyl)-1,3-oxazol-4-yl]acetate
• CAS: 401791-21-7
• 化学式: C₁₅H₁₇NO₃
• 分子量: 259.305
• InChiKey: IDVDTNDUXYNAMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5-methyl-2-phenethyl-oxazol-4-yl)-acetic acid methyl ester 在 sodium hydroxide 、 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.67h， 生成 2-(5-methyl-2-phenethyl-oxazol-4-yl)-ethanol
  参考文献：
  名称：

  Application of the Dakin−West Reaction for the Synthesis of Oxazole-Containing Dual PPARα/γ Agonists

  摘要：

  An improved method for the preparation of a series of oxazole-containing dual PPARalpha/gamma agonists is described. A synthetic sequence utilizing a Dakin-West reaction was devised that allows for the introduction of the oxazole ring either late in the synthetic sequence via aminomalonate-derived chemistry or in pivotal SAR intermediates derived from aspartic acid.

  DOI：

  10.1021/jo026655v
• 作为产物：
  描述：

  4-oxo-3-(3-phenyl-propionylamino)-pentanoic acid methyl ester 在 硫酸 、 乙酸酐 作用下， 生成 (5-methyl-2-phenethyl-oxazol-4-yl)-acetic acid methyl ester
  参考文献：
  名称：

  Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

  摘要：

  由以下结构式（I）表示的化合物及其药用可接受的盐、溶剂合物和水合物，其中：n为2、3或4，W为CH2、CH（OH）、C（O）或O；R1为未取代或取代的芳基、杂环芳基、环烷基、杂环烷基、芳基-烷基、杂环芳基-烷基、环烷基-烷基或叔丁基；R2为H、烷基、卤代烷基或苯基；Y为未取代或取代的噻吩-2,5-二基或苯基；R3为烷基或卤代烷基；R4为取代或未取代的苯基、萘基、1,2,3,4-四氢萘基、喹啉基、吡啶基或苯并[1,3]二氧杂环-5-基团；R5为H、烷基或氨基烷基；用于调节过氧化物酶增殖物激活受体，特别是在糖尿病治疗中。

  公开号：

  US20040097590A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR<br/>[FR] COMPOSES HETEROCYCLIQUES UTILISES COMME MODULATEURS DES RECEPTEURS ACTIVES PROLIFERATEURS DU PEROXYSOME (PPAR), UTILES DANS LE TRAITEMENT ET/OU LA PREVENTION DE TROUBLES MODULES PAR UN PPAR
  申请人：LILLY CO ELI

  公开号：WO2005051945A1

  公开（公告）日：2005-06-09

  The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种式(I)的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，该化合物在治疗或预防由过氧化物酶体增殖激活受体（PPAR）介导的疾病中具有用途，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉硬化以及与X综合征和心血管疾病相关的其他疾病。
• Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
  申请人：——

  公开号：US20040097590A1

  公开（公告）日：2004-05-20

  Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH 2 , CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus. 1

  由以下结构式（I）表示的化合物及其药用可接受的盐、溶剂合物和水合物，其中：n为2、3或4，W为CH2、CH（OH）、C（O）或O；R1为未取代或取代的芳基、杂环芳基、环烷基、杂环烷基、芳基-烷基、杂环芳基-烷基、环烷基-烷基或叔丁基；R2为H、烷基、卤代烷基或苯基；Y为未取代或取代的噻吩-2,5-二基或苯基；R3为烷基或卤代烷基；R4为取代或未取代的苯基、萘基、1,2,3,4-四氢萘基、喹啉基、吡啶基或苯并[1,3]二氧杂环-5-基团；R5为H、烷基或氨基烷基；用于调节过氧化物酶增殖物激活受体，特别是在糖尿病治疗中。
• [EN] OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS<br/>[FR] DÉRIVÉS D'ACIDE OXAZOLYL-ARYLPROPIONIQUE ET LEUR UTILISATION COMME AGONISTES DES PPAR
  申请人：LILLY CO ELI

  公开号：WO2002016331A1

  公开（公告）日：2002-02-28

  Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

  以下结构式(I)所代表的化合物及其药学上可接受的盐、溶剂化物和水合物，其中：n为2、3或4，W为CH2、CH(OH)、C(O)或O；R1为未取代或取代的芳基、杂环芳基、环烷基、杂环烷基、芳基烷基、杂环芳基烷基、环烷基烷基或叔丁基；R2为H、烷基、卤代烷基或苯基；Y为未取代或取代的噻吩-2,5-二基或苯基；R3为烷基或卤代烷基；R4为取代或未取代的苯基、萘基、1,2,3,4-四氢萘基、喹啉基、吡啶基或苯并[1,3]二噁烷-5-基团；R5为H、烷基或氨基烷基；在调节过氧化物酶体增殖物激活受体方面有用，特别是在糖尿病治疗中。
• Peroxisome proliferator activated receptor agonists
  申请人：Brooks Alisa Dawn

  公开号：US20050245584A1

  公开（公告）日：2005-11-03

  Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH 2 , CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

  以下结构式（I）表示的化合物及其药学上可接受的盐、溶剂合物和水合物，其中：n为2、3或4，W为CH2、CH（OH）、C（O）或O；R1为未取代或取代的芳基、杂芳基、环烷基、杂环烷基、芳基-烷基、杂芳基-烷基、环烷基-烷基或叔丁基；R2为H、烷基、卤代烷基或苯基；Y为未取代或取代的噻吩-2,5-二基或苯基；R3为烷基或卤代烷基；R4为取代或未取代的苯基、萘基、1,2,3,4-四氢萘基、喹啉基、吡啶基或苯并[1,3]二噁烷-5-基团；R5为H、烷基或氨基烷基；对于调节过氧化物酶体增殖物活化受体尤其在糖尿病治疗中有用。
• Modulators of peroxisome proliferator activated receptors (ppar)
  申请人：Gossett Stacy Lynn

  公开号：US20050075378A1

  公开（公告）日：2005-04-07

  The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.

  本发明涉及一种I式化合物，以及其药学上可接受的盐、溶剂、水合物或立体异构体，该化合物在治疗X综合征、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉硬化以及与X综合征相关的其他疾病以及心血管疾病方面有用。